Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Curis is a biotechnology company focused on the development of emavusertib (CA-4948), an IRAK4 inhibitor for hematologic malignancies. The company also holds a collaboration with Genentech/Roche for the commercialization of Erivedge (vismodegib), which generates royalty revenue. As of December 31, 2024, the company had 34 employees.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Revenue | $10.9 million | $10.0 million |
| Net Loss | $(43.4) million | $(47.4) million |
| Operating Cash Flow | $(39.6) million | $(38.4) million |
| Cash and Cash Equivalents (Dec 31, 2024) | $20.0 million | $26.7 million |
| Accumulated Deficit | $(1.24) billion | $(1.20) billion |
| Liability Related to Sale of Future Royalties | $34.2 million (Total) | $42.6 million (Total) |
Note: Revenue is derived almost entirely from royalties on Erivedge sales. A significant portion of these royalties is contractually obligated to be paid to third-party purchasers under the Oberland Purchase Agreement.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 9% year-over-year to $10.9 million, driven by continued Erivedge sales.
- Expense Reduction: Research and Development (R&D) expenses decreased 2% to $38.6 million due to lower clinical and consulting costs. General and Administrative (G&A) expenses decreased 10% to $16.8 million.
- Financing Activity: The company completed a registered direct offering and concurrent private placement in October 2024, raising approximately $10.8 million in net proceeds. In March 2025 (post-period), the company completed another offering raising approximately $9.0 million in net proceeds.
- Investment Portfolio: All short-term investments matured by December 31, 2024, resulting in a decrease in total assets compared to 2023.
Guidance, Outlook, and Risks
Going Concern Warning
Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern. The independent auditor has included an emphasis of matter paragraph regarding this uncertainty. The company expects its cash resources (including the March 2025 offering) to fund operations only into the fourth quarter of 2025.
Outlook and Guidance
- Emavusertib Development: The company is advancing emavusertib in Phase 1/2 trials for Primary Central Nervous System Lymphoma (PCNSL) and Acute Myeloid Leukemia (AML). In March 2025, the company announced productive meetings with the FDA and European CHMP regarding potential accelerated regulatory pathways (NDA in the U.S. and CMA in Europe).
- Funding Needs: Substantial additional capital is required immediately to fund the development of emavusertib through regulatory approval and commercialization. Failure to raise capital could force the company to delay, reduce, or eliminate its R&D program or seek bankruptcy protection.
Key Risks and Contingencies
- Oberland Purchase Agreement: The company sold rights to a portion of future Erivedge royalties. An event of default could trigger a repurchase obligation (Put/Call Price) estimated at approximately $110.0 million as of December 31, 2024. Counsel for the purchasers previously alleged defaults in March 2023, which the company disputes.
- Regulatory Uncertainty: Success depends on clinical trial results and regulatory approvals, which are uncertain. The company has never obtained marketing approval for a drug candidate.
- Nasdaq Listing: In February 2025, the company received a deficiency letter from Nasdaq regarding the Market Value of Listed Securities (MVLS) requirement. The company has 180 days to regain compliance.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $20.0 million cash balance plus the $9.0 million March 2025 proceeds to fund operations through Q4 2025 given the high burn rate.
- Oberland Default Status: Confirm the current status of the alleged defaults under the Oberland Purchase Agreement and the potential $110 million repurchase liability.
- Nasdaq Compliance: Monitor the company's progress in regaining compliance with Nasdaq's $35 million MVLS requirement by August 20, 2025.
- Clinical Data: Review upcoming data releases from the TakeAim Lymphoma and Leukemia studies expected in late 2025.
- Future Financing: Assess the likelihood and terms of future equity financings required to bridge the funding gap beyond late 2025.